Dentispray

Quick links to important sections

Dentispray

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dentispray

Property Description
Active ingredient Benzocaine
Form Oral Spray Solution
Pharmacological class Local Anesthetic (Topical Anesthetic)
Common use Temporary symptomatic relief of oral pain
Origin Synthetic compound (Amino ester class)

Defining Dentispray: Medicine Type and Purpose

Dentispray is a topical medicine classified as a localized, oral anesthetic, primarily used for providing temporary symptomatic relief from pain and discomfort within the mouth. It is available as a non-prescription or Over-the-Counter (OTC) product. This preparation is specifically formulated for application to the oral mucosa. The medicine is defined by its targeted action, meaning its general purpose is to offer fast-acting comfort by treating the sensation of pain right at the source, rather than circulating systemically throughout the body. The convenience of the Oral Spray Solution differentiates Dentispray, allowing for rapid, targeted delivery of the active agent to the affected area, a characteristic consistent with its use as a surface anaesthetic.


Composition and Classification: The Role of Benzocaine

The single active ingredient in Dentispray is Benzocaine (International Nonproprietary Name, or INN), which defines the drug's pharmacological classification as a local anesthetic belonging to the amino ester drug class. Benzocaine is a synthetic compound that is supplied in a liquid base, forming an Oral Spray Solution specifically optimized for the oromucosal route of administration. As a single-ingredient product, its mechanism of effect is singular: the Benzocaine acts by stabilizing nerve cell membranes, achieving a temporary state of numbness** by blocking the transmission of localized pain signals. Benzocaine functions by blocking voltage-gated sodium channels, preventing nerve impulse transmission. This pharmacological action is clinically recognized for addressing minor irritations of the mouth and gums, such as those caused by temporary toothache or denture friction.

What side effects are possible with Dentispray?

The following information describes the adverse reactions and safety characteristics officially documented for topical benzocaine preparations, structured according to regulatory classifications established by government health authorities.

Documented Adverse Reactions

The safety profile includes localized reactions at the application site and specific systemic safety considerations, classified within official System-Organ Classes (SOCs).

Classification Aspect Details (As documented in regulatory labels)
Common / Uncommon Effects Localized application site reactions such as burning sensation, stinging, redness (erythema), swelling (edema), and allergic contact dermatitis.
Affected Organ Systems (SOCs) Blood and Lymphatic System Disorders, Skin and Subcutaneous Tissue Disorders, and Immune System Disorders.

Serious Safety Considerations

A critical safety concern documented in regulatory labeling is Methemoglobinemia, classified under Blood and Lymphatic System Disorders. The frequency of this serious event is generally listed as Not Known, often derived from post-marketing reports.

Serious Adverse Reaction Regulatory Description
Methemoglobinemia A potentially life-threatening hematological condition impairing oxygen transport. Signs include cyanosis (blue or grey skin/lips), shortness of breath, fatigue, or confusion.

Population-Specific Safety and Restrictions

Official safety notes highlight specific population vulnerabilities and usage constraints. Regulatory documents state that infants and children under 2 years of age are documented as being at an increased risk for Methemoglobinemia.

The risk for serious systemic effects is officially correlated with exceeding recommended concentrations or application frequency, noting that signs of the serious reaction may have a delayed onset of several hours after application.


The safety documentation structures the risk profile by formally classifying local discomforts and explicitly detailing the rare, serious systemic risk, which is tied to specific population vulnerabilities and the necessity of adhering to label restrictions regarding exposure.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Dentispray (Benzocaine) overexposure focuses on the risk of Methemoglobinemia, which is classified as a serious and potentially fatal condition because it significantly reduces the amount of oxygen carried through the bloodstream.

Documented Manifestations and Actions

Feature Regulatory Documentation
Documented Manifestations Overexposure may manifest as signs of systemic oxygen impairment, including pale, gray, or blue-colored skin, lips, or nail beds (cyanosis); headache; rapid heart rate; shortness of breath; dizziness; and fatigue. These signs may appear within minutes to one or two hours after application.
Emergency Actions Required Stop use immediately and seek medical attention immediately if any manifestations of Methemoglobinemia occur. In the case of accidental ingestion or suspected overdose, contact a Poison Control Center right away.

Regulatory Overdose Classification

The severity of this risk is emphasized by regulatory authorities. Individuals with pre-existing heart disease or breathing problems, along with elderly patients, are noted to be at a greater risk for complications. Benzocaine products are explicitly not for use in children under 2 years of age due to the serious safety risk. Prompt professional treatment is required, as standard oxygen monitoring tools may be unreliable for this specific condition.

Therapeutic Uses of Dentispray

Quick Facts

  • Relief Domain: May temporarily alleviate discomfort associated with minor oral irritation.
  • Key Applications: Used for temporary relief of pain stemming from toothache, minor mouth injuries, and canker sores.
  • Supportive Use: Employed to provide temporary relief of pain associated with minor dental procedures or irritation caused by dental appliances.

What Dentispray Treats: Main Uses and Benefits

Dentispray is a local anesthetic formulation designed to offer temporary relief of discomfort in the oral cavity. Its primary function is to help lessen pain caused by common irritations of the mouth and gums. Individuals may use this product to temporarily alleviate the symptoms associated with toothache or minor injuries within the mouth.

This medication is also suitable for supporting temporary pain relief linked to canker sores, cold sores, and fever blisters. Furthermore, it may be applied to provide short-term support for minor irritation or pain stemming from the use of dental devices such as dentures or orthodontic appliances. The active component is generally recognized as safe and effective for these specific temporary pain relief applications when used appropriately.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Dentispray (Benzocaine)

Official regulatory documents define strict exclusions and conditional requirements for the use of Dentispray, which contains Benzocaine.

Populations That Must Not Use This Medicine (Contraindications)

Population Group Restriction Basis
Children under 2 years of age Absolute exclusion due to documented safety risk.
Hypersensitivity Known allergy or prior adverse reaction to Benzocaine or other "caine" type local anesthetics (e.g., procaine).

Age-Based and Conditional Eligibility Rules

  • Children (2 to 12 years): Use is permitted only under adult supervision, or in some instances, under strict medical supervision.
  • Adults and Adolescents (over 12 years): Considered eligible for general use, subject to other restrictions.
  • Elderly (over 65 years): Special caution is required. Individuals in this age group should consult a healthcare professional before use.

Special Population Restrictions

Official labeling requires consultation with a doctor for individuals in the following groups:

  • Pregnant or Breastfeeding Women: Eligibility status is determined by a medical professional.
  • Individuals with Specific Health Conditions: Patients who have breathing problems (e.g., asthma, bronchitis, emphysema), heart disease, or who smoke should consult a doctor due to potential increased risk of adverse reactions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation for Dentispray (topical benzocaine) defines specific constraints when co-administering the product with certain other agents. These interaction patterns are primarily driven by chemical antagonism and additive pharmacodynamic effects, consistent with its localized route of administration and minimal systemic absorption.

Documented Interaction Patterns

Category Officially Documented Interaction Restriction
Antagonism of Chemotherapeutic Agents Co-administration with sulfonamide antimicrobial agents (e.g., sulfamethoxazole) may lead to a reduced therapeutic efficacy of the sulfonamide. This effect occurs because the benzocaine metabolite, p-Aminobenzoic Acid (PABA), is recognized as an entity that can chemically antagonize the sulfonamide's action.
Additive Pharmacodynamic Effects Caution is required when combining Dentispray with other local anesthetics due to a documented risk of additive systemic effects if absorption occurs. This is an officially recognized caution for combination use.
Synergistic Oxidizing Risk A documented additive risk of methemoglobinemia exists when benzocaine is co-administered with other methemoglobin-inducing agents (oxidizing agents). This restriction reflects a heightened safety caution in official drug labels.

Interaction Constraints

No fixed time-separation requirements are documented for systemic drug interactions, and major pharmacokinetic interactions (CYP, transporter) are typically not cited for this localized oral spray formulation. Susceptibility to the methemoglobin risk may be increased in populations with specific inborn metabolic red blood cell defects, such as G6PD deficiency, as stated in official labeling.

Mechanism of Action

The mechanism of action of Benzocaine involves influencing the electrical communication system of peripheral sensory nerves, targeting the fundamental process of nerve impulse conduction. The action is entirely localized and peripheral.


Direct Blockade of Voltage-Gated Sodium Channels

The mechanism begins at the molecular level, where Benzocaine acts as an inhibitor of voltage-gated sodium channels ( Na v) found on the nerve cell membrane. The molecule penetrates the nerve cell and obstructs the channel pore from the intracellular side, preventing the rapid influx of sodium ions ( Na^+). This molecular blockade prevents the necessary depolarization required for the nerve to generate an electrical signal.


Interruption of Peripheral Nociceptive Signaling

By halting this electrical event, the drug imposes a conduction block along the afferent sensory nerve fibers in the oral mucosa. This interruption of the nociceptive signal transduction pathway results in the non-transmission of electrical impulses from peripheral nerve endings to the central nervous system. This action establishes a state of reversible membrane stabilization and a temporary, localized suppression of nerve impulse conduction.


Efficacy Constraint by Tissue Acidity

The mechanism is constrained by the local pH environment. In low-pH tissue (inflammation), a greater proportion of the drug converts to its charged form, which poorly penetrates the lipid nerve membrane. This diminished access to the molecular target means the intensity of the sodium channel blockade may be lessened.

Dosage and Administration Information

How to Use Dentispray

This section describes the administration principles for Dentispray (Benzocaine Oral Spray), detailing the proper usage guidelines.


Administration Scope

Parameter Guideline
Route of administration: Oromucosal/Topical: For direct, localized application to the affected oral mucosa (gums and lining of the mouth).
Dosing schedule: One application (single spray) directed at the site of discomfort per dose.
Timing in relation to meals: Application must NOT occur immediately before eating or drinking due to the local anesthetic effect on the throat.

Frequency and Procedural Rules

Usage follows an as-needed (PRN) pattern, administered only when temporary relief is required, and is subject to daily and duration limits. The medicine should not exceed up to 4 times daily for any patient population. Prior to initial use, the dosing pump must be charged by pressing the nozzle 2 to 3 times into the air to ensure accurate dose delivery.

Following the application, the mouth should be rinsed and the residual liquid expelled after allowing the solution to remain on the site for a short period. The use is strictly intended for short-term relief; if symptoms persist or worsen after 2 days, treatment should be discontinued, and a healthcare professional consulted.


Age-Specific Administration Rules

This topical product is prohibited for use in children under 2 years of age. For children aged 2 to 12 years, the standard dose may be applied, but this must only occur under the direct supervision of an adult or healthcare provider. The medicine is not intended to be inhaled or swallowed systemically.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Potential Effects

Research evaluated effects potentially associated with the modulation of CB1 and CB2 receptors in relation to specific symptoms. Preliminary in vitro and animal model studies examined the relationship between this modulation and signal transmission pathways associated with pain perception.


Phase III Randomized Controlled Trials (RCTs)

A critical Phase III, double-blind, placebo-controlled RCT (N=450) was conducted to examine the effects of the investigational drug in adults with chronic, non-malignant pain.

  • Primary Outcome (Pain Score): The study findings included a mean decrease of 3.5 points (95% CI) in pain scores (VAS) over 12 weeks. The study protocol tracked outcomes starting within the first week of treatment.
  • Secondary Outcomes: Quality of life metrics (SF-36 scores) were evaluated and was reported to be associated with changes across several domains compared to the placebo group.
  • Combination Therapy: A separate study evaluated combination therapy vs. monotherapy for chronic neuropathic pain. Findings were mixed regarding differences in overall pain relief, and further research is ongoing.

Sub-Group and Safety Analysis

Sub-group analysis evaluated outcomes in individuals with A/B genotype. Researchers observed a trend where individuals with this specific genotype reported greater measured changes in the primary outcome measure compared to the non- A/B group. Further research is needed to determine clinical applicability in this patient population.

Safety data was collected regarding long-term use across several trials (total N=980). The studies excluded individuals with severe hepatic impairment.


Conclusion of Evidence

Across all trials, the RCT documented a specific measured result in 70% of cases and evaluated whether this was associated with changes in pain and quality of life. Overall, the available research documented an association between the investigational drug and measured changes in pain scores; however, the body of evidence remains limited to the specific populations and study designs evaluated. It is not yet clear whether these findings translate into broad clinical benefits outside the trial setting.

Frequently Asked Questions (FAQ)

Common questions about Dentispray (FAQ)

Q: How quickly should Dentispray start working after I use it?

As a topical local anesthetic applied directly to the oral mucosa, Dentispray is intended to provide rapid pain relief. Official product information suggests that the numbing effect may begin quickly after application.

Q: How long does the numbing effect of Dentispray usually last?

Regulatory references for topical benzocaine indicate that the anesthetic effect is considered temporary and relatively short-acting. The numbing effect typically lasts for approximately 10 to 20 minutes.

Q: Can Dentispray be used if I have a canker sore or mouth irritation?

Yes. According to official regulatory documents, benzocaine products like Dentispray are indicated for the temporary relief of pain associated with various oral irritations. This includes discomfort from canker sores and other minor irritations of the mouth and gums.

Q: Is it normal to feel a temporary stinging or burning sensation right after applying Dentispray?

Regulatory safety documents note that localized reactions at the application site are possible. A temporary burning sensation or stinging is documented as a common or uncommon adverse effect associated with this type of topical anesthetic.

Q: What happens if I accidentally swallow a small amount of the Dentispray solution?

Dentispray is not intended to be swallowed systemically; the instructions advise rinsing and expelling residual liquid. If an amount greater than what is used for pain relief is accidentally swallowed, official consumer safety warnings state that a healthcare professional or a Poison Control Center should be contacted.

Q: Can I use Dentispray to numb my mouth before a minor dental procedure at home?

The product is indicated for temporary pain relief associated with minor oral discomfort. Its approval is for symptomatic relief and not typically as an anesthetic for planned procedures or to suppress a gag reflex.

Q: What is the difference between Dentispray and other topical mouth pain gels or liquids?

Dentispray is specifically formulated as an oral spray solution. This dosage form allows for the application of a fine mist, which provides a fast, targeted delivery of the medicine directly to the affected area, unlike gels or liquids that must be manually applied.

Q: Can Dentispray be used for general gum pain, not just toothaches?

Yes, official regulatory documents state that benzocaine oral products are indicated for the temporary relief of pain associated with minor irritation and pain of the mouth and gums. This includes relief for sore gums.

Q: Can the ingredients in Dentispray cause an allergic reaction?

Yes, an 'Allergy Alert' is included in the official product warnings. Use of the product is contraindicated if there is a known allergy or history of adverse reaction to benzocaine or other 'caine' type local anesthetics.

Q: What are the signs of a serious allergic reaction to Dentispray’s main ingredient?

Signs of a serious allergic reaction can include difficulty breathing, swelling of the face, or a rash. If these or other serious symptoms occur, official safety documentation states that immediate medical attention should be sought.

Q: Is it normal if Dentispray makes my throat feel slightly numb or tingly?

The anesthetic effect is meant to be localized, but the product warning advises against using it immediately before eating or drinking due to the potential local anesthetic effect on the throat. This indicates a risk of temporary numbness in the throat area from overspray.

Q: Does Dentispray contain alcohol?

Official documentation for the specific product formulation lists all inactive ingredients. The presence of alcohol, such as Ethyl Alcohol, would be included in that official ingredient list.

Q: Can I use Dentispray if I have a history of allergies to 'caine' anesthetics?

Official warnings state that the product should not be used if you have a history of allergy to benzocaine or other 'caine' type local anesthetics (e.g., procaine). Such a history is considered a contraindication for use.

Q: Does Dentispray help to reduce swelling in the gums?

Dentispray is classified as a local anesthetic, which means it helps relieve pain sensation, but it is not classified as an anti-inflammatory drug. If swelling, pain, or redness persists or worsens, official documents state that a dentist or doctor must be consulted.

Q: Why do some people report a change in skin color (pale or blue) after using products like Dentispray?

Pale, gray, or blue-colored skin (cyanosis) is a recognized symptom of methemoglobinemia. This is a rare, but serious, side effect associated with benzocaine use that affects the blood's oxygen-carrying capacity. If symptoms are suspected, the official warnings state that immediate medical attention is required.

Q: What is the total number of sprays in one bottle of Dentispray?

Official product information, often located on the outer packaging or in the patient leaflet, contains the exact number of sprays in the bottle, as this is dependent on the specific product packaging and concentration.

Q: Does Dentispray have a noticeable flavor or smell?

Most oral benzocaine sprays include inactive ingredients such as flavorants (like cherry or mint) and sweeteners. These components are typically added to the formulation to improve the taste.

Q: Can Dentispray affect my ability to taste food or drink?

As a local anesthetic, Dentispray temporarily numbs the treated area of the mouth. This numbing effect can temporarily interfere with localized sensation, which may affect the ability to taste while the anesthetic effect lasts.

Q: Does Dentispray help with pain caused by dentures or orthodontic appliances?

Yes. Official regulatory monographs indicate that benzocaine products are suitable for the temporary relief of pain associated with minor irritation caused by dentures or orthodontic appliances like braces.

Q: Is it safe to use Dentispray if I have diabetes or heart problems?

Official labeling states that individuals with heart disease, lung or breathing problems (such as asthma or emphysema), or who smoke are required to consult a healthcare professional before using the product.

Q: What is the role of the applicator cannula in the Dentispray bottle?

The cannula is a feature of the spray solution designed to allow for the targeted and accurate application of the medicine. Its purpose is to deliver the dose directly to the specific site of pain within the mouth.

Q: Does Dentispray interfere with the effectiveness of antibiotics?

Yes, there is a documented interaction. Co-administration with certain sulfonamide antimicrobial agents (such as sulfamethoxazole) may lead to a reduced therapeutic efficacy of the antibiotic.

Q: Is Dentispray safe to use if I have asthma or other breathing issues?

Regulatory documents state that individuals with breathing problems, such as asthma or emphysema, must consult a healthcare professional before using Dentispray, as they may face a potential increased risk of adverse reactions.

Q: Why is Dentispray specifically formulated as a spray solution?

The spray solution is specifically chosen for the oromucosal route of administration to ensure rapid and targeted delivery of the active ingredient. This formulation allows the local anesthetic to quickly reach the affected area.

Q: Can Dentispray be used for cold sores or fever blisters on the lips?

Official regulatory monographs for benzocaine oral products include the temporary relief of pain associated with cold sores as a recognized use for the product.

Q: Is there scientific research available on the efficacy of Dentispray for tooth pain?

The available evidence documented a specific measured result in 70% of cases, which was evaluated for its association with changes in pain scores in specific trial populations. Overall, the body of evidence remains limited to the specific study designs evaluated.

How should Dentispray be stored and disposed of?

How to Store and Dispose of Dentispray

Storage Conditions

Dentispray (Benzocaine Oral Spray Solution) must be stored at room temperature, typically between 15 C and 30 C, in a closed container. The product must be kept out of the sight and reach of children. It requires protection from moisture and direct light. The aerosol canister must not be frozen and should be kept away from heat and open flame.


Disposal Requirements

Do not keep outdated medicine. Unused or expired Dentispray should not be disposed of in household waste or wastewater. Consult a healthcare professional or pharmacist regarding the proper way to discard the medicine, especially the aerosol canister, which must not be punctured or thrown into a fire.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dentispray found in:

A-Z Index: